drugset / Trial / NCT01968967

Randomized Clinical Trial of Bococizumab (PF-04950615; RN316) in Subjects With Hyperlipidemia or Mixed Dyslipidemia at Risk of Cardiovascular Events

NCT01968967

Phase 3 Completed 2139 enrolled Pfizer
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is a multicenter, randomized study in subjects with high cholesterol receiving highly effective statins to assess the efficacy, safety and tolerability of Bococizumab (PF-04950615;RN316) to lower LDL-C.

Timeline

Start
2013-10-29
Primary completion
2016-07-05
Completion
2017-07-10

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Bococizumab Monoclonal antibody 150 mg Subcutaneous

Indications